Loading...
Printed on 7/20/2026
For informational purposes only. This is not medical advice.
The Charlson Comorbidity Index (CCI) is a weighted comorbidity score originally developed to estimate long-term mortality risk associated with chronic disease burden. It is widely used in clinical research, inpatient risk stratification, and outcome-adjusted care planning.
Formula: CCI is the sum of weighted comorbidity points plus age points.
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
Assign points for each condition present: 1 point each for MI, CHF, peripheral vascular disease, cerebrovascular disease, dementia, COPD, connective tissue disease, peptic ulcer disease, mild liver disease, diabetes without complications. 2 points each for hemiplegia/paraplegia, moderate-severe CKD, diabetes with end-organ damage (neuropathy, retinopathy, nephropathy), solid tumor (non-metastatic). 3 points for moderate-severe liver disease (cirrhosis, portal hypertension). 6 points each for metastatic solid tumor and AIDS.
Add age points to the comorbidity score: age below 50 = 0 points; age 50-59 = +1 point; age 60-69 = +2 points; age 70-79 = +3 points; age 80 and above = +4 points. The age-adjusted CCI (ACCI) is the most widely used version in published literature, as age independently predicts mortality beyond comorbidity burden.
ACCI 0 = 98% 10-year survival; ACCI 1-2 = 91%; ACCI 3-4 = 77%; ACCI 5-6 = 53%; ACCI above 5 = approximately 21% (some sources cite 21% for scores above 5). Higher scores predict lower long-term survival for all-cause mortality. These estimates are from the original 1987 cohort and performance varies in modern populations with improved cancer and HIV treatments.
Surgeons, anesthesiologists
CCI predicts postoperative 30-day and 1-year mortality in patients undergoing major elective surgery. Higher CCI scores indicate greater baseline disease burden and reduced physiologic reserve. While RCRI (Revised Cardiac Risk Index) better predicts perioperative cardiac events, CCI provides broader comorbidity risk assessment including cancer, liver disease, and neurological conditions. CCI above 3 is associated with significantly increased surgical mortality.
Clinical researchers, epidemiologists
CCI is the most widely used comorbidity adjustment tool in clinical research. When comparing outcomes between patient groups, CCI controls for baseline disease burden as a covariate. The ICD-code based CCI (Deyo/Quan algorithms) allows automated calculation from administrative data in large database studies — enabling adjustment across millions of records in health services research.
Trial coordinators, oncologists
Many clinical trials exclude patients above a CCI threshold to ensure a more homogeneous, less complex study population. Alternatively, CCI is used as a stratification variable to ensure balanced comorbidity distribution across treatment arms. Cancer trials particularly use CCI to control for non-cancer comorbidity burden when evaluating cancer-specific interventions.
Intensivists, critical care physicians
CCI is used as a baseline comorbidity adjustment alongside acute severity scores (APACHE II, SOFA) in ICU mortality modeling. APACHE II captures acute physiologic derangement; CCI captures chronic disease burden. Combined, they better predict ICU and hospital mortality than either alone. CCI score above 5 is associated with significantly higher ICU mortality independent of acute illness severity.
Oncologists, geriatric oncologists
In cancer patients, CCI controls for non-cancer comorbidities when evaluating cancer outcomes. Comorbidity burden significantly impacts treatment tolerance, performance status decline, and survival in cancer patients independent of tumor stage and histology. High CCI (above 3) in cancer patients predicts inability to tolerate aggressive chemotherapy, higher treatment-related mortality, and shorter overall survival regardless of cancer stage.
CCI was validated for 10-year mortality prediction, not short-term surgical risk. For perioperative cardiac risk, use RCRI (Revised Cardiac Risk Index) instead. For overall frailty and functional status, consider Clinical Frailty Scale or ECOG Performance Status. For ICU acute mortality, use APACHE II or SOFA. CCI has the best evidence base for long-term outcomes research and comorbidity adjustment in population studies.
The original 1987 Charlson index did not include age. The age-adjusted Charlson Comorbidity Index (ACCI) adds 1 point per decade above 40. When reading literature, verify whether CCI (without age) or ACCI (with age points) was used — the two produce different scores for the same patient. Modern research almost universally uses ACCI. This calculator uses ACCI as the default scoring.
CCI was designed from data collected in the 1970s-1980s and does not include conditions recognized as major mortality predictors in modern medicine: obesity (BMI above 40), frailty, depression, functional decline, sarcopenia, or social determinants of health. For comprehensive risk assessment in elderly patients, supplement CCI with a frailty assessment (Clinical Frailty Scale, FRAIL questionnaire) and ECOG performance status.
Many EHRs automatically calculate CCI from ICD diagnosis codes using the Deyo or Quan algorithms. However, coding errors (overcoding, undercoding, outdated codes) can significantly inflate or deflate the score. Retrospective research using automated CCI should validate against chart review for the conditions driving the highest-weight items (metastatic cancer, liver disease, AIDS) which are most vulnerable to miscoding.
The 6-point weighting for metastatic solid tumor and AIDS reflects the nearly uniformly fatal prognosis of these conditions in the 1980s when the index was developed. Modern cancer therapies (immunotherapy, targeted agents) and HIV treatment (HAART) have dramatically improved survival. A patient with controlled HIV or stable metastatic melanoma on immunotherapy has far better prognosis than the 6-point weight implies. Use CCI scores cautiously for these conditions in contemporary patients.
High CCI scores identify patients with very poor long-term prognosis who may benefit from early palliative care discussions. CCI above 7 (age-adjusted) is associated with less than 50% 5-year survival in most cohorts. This threshold has been used to identify patients unlikely to benefit from aggressive interventions and appropriate for goals-of-care conversations, transplant listing review, or resource allocation considerations.
The Elixhauser Comorbidity Index (developed 1998) identifies 30 comorbidities and is widely used in hospital administrative database research. Unlike CCI's weighted sum, Elixhauser produces a profile of 30 binary flags used as separate covariates. The van Walraven weighted Elixhauser score (2009) converts it to a single index. Both CCI and Elixhauser are valid; study requirements and data source determine which is more appropriate.
The original Charlson (1987) derivation cohort consisted of 559 medical inpatients. External validation has been performed in surgical, oncologic, renal transplant, and community populations — but performance varies. The Quan et al. updated ICD-10 algorithm (Med Care 2005) improved CCI's performance in administrative database populations. Always check whether CCI has been validated in the specific population you are studying.
Charlson Comorbidity Index developed by Charlson et al. (J Chron Dis 1987) from 559 medical inpatients. Updated by Deyo et al. (J Clin Epidemiol 1992) for ICD-9 administrative database coding. Quan et al. (Med Care 2005) revised for ICD-10 codes. Updated CCI (Quan et al., Med Care 2011) showed C-statistic 0.82 for 1-year mortality. Elixhauser Comorbidity Index: Elixhauser et al. (Med Care 1998); van Walraven weighted score (Med Care 2009). Age-adjusted CCI 10-year survival data: Charlson et al. (J Chron Dis 1987) and updated by Deyo et al. CCI in cancer: Cronin-Fenton et al. (Eur J Cancer 2007).
Higher CCI totals indicate higher systemic disease burden and reduced physiologic reserve.
Use for baseline risk characterization, outcomes discussions, and risk-adjusted comparisons in clinical and research settings.
CCI is not diagnosis-specific and may not capture acute physiologic severity or nuances of modern therapy response.
For related assessments, see ASA Class, ECOG Status and Clinical Frailty Scale.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Classify preoperative physical status using the ASA I–VI system for anesthetic risk stratification. ASA III+ indicates significant systemic disease requiring special perioperative planning and precautions.
OpenOncologyClassify cancer patient performance status using the ECOG 0–5 scale. ECOG 0–1: eligible for standard chemotherapy. ECOG 2: limited self-care. ECOG 3+: significantly impaired, clinical trial caution.
OpenGeriatricsAssess frailty using the Rockwood Clinical Frailty Scale (CFS 1–9): Very Fit to Terminally Ill. Used for hospice eligibility, prognostication, ICU triage, surgical risk stratification, and goals-of-care discussions.
OpenSurgeryEstimate perioperative major cardiac event risk for non-cardiac surgery using the 6-factor Lee RCRI model.
Open